Impact of the Implementation of a Referral Veno-venous Extracorporeal Membrane Oxygenation Centre on Mortality (ECMO UNIT)
January 28, 2026 updated by: Centre Hospitalier Universitaire Dijon
Current evidence suggest that regrouping patient supported by veno-venous ECMO in high-volume centre could improve outcome. A dedicated ECMO unit was implemented in Dijon.
The objective of the present study was to evaluate the implementation of this unit. The hypothesis was that patient taken care within this structured care system would have lower mortality.
This research comprises a retrospective observational study conducted in Dijon university hospital
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
172
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Dijon, France, 21000
- Chu Dijon Bourogne
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients supported by veno-venous ECMO
Description
Inclusion Criteria:
- patient in an adult Dijon ICUs supported by veno-venous ECMO
- patient hospitalized between January the 1st 2011 and June the 30th 2021
Exclusion Criteria:
- Refusal to participate,
- patient admitted to pediatric ICU
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
ECMO VV dedicated unit
Patient having benefited from an ECMO within the structured care unit
|
Collection of adverse events, of mortality, length of hospitalization
|
|
ECMO VV without dedicated unit
Patient having benefited from an ECMO without the structured care unit
|
Collection of adverse events, of mortality, length of hospitalization
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Mortality rate
Time Frame: 90 days
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Rate of ECMO adverse events
Time Frame: through study completion, an average of 3 years
|
through study completion, an average of 3 years
|
|
Hospital length of stay
Time Frame: through study completion, an average of 3 years
|
through study completion, an average of 3 years
|
|
ICU length of stay
Time Frame: through study completion, an average of 3 years
|
through study completion, an average of 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2021
Primary Completion (Actual)
November 1, 2021
Study Completion (Actual)
December 1, 2021
Study Registration Dates
First Submitted
October 21, 2021
First Submitted That Met QC Criteria
December 9, 2021
First Posted (Actual)
December 10, 2021
Study Record Updates
Last Update Posted (Actual)
January 29, 2026
Last Update Submitted That Met QC Criteria
January 28, 2026
Last Verified
January 1, 2026
More Information
Terms related to this study
Other Study ID Numbers
- NGUYEN 2021-3
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.